title: Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites.
abstract: To compare the osteoinductive activity of recombinant human bone morphogenetic protein-2 (rhBMP-2) at various sites in rats, 5 microg of rhBMP-2 were implanted into various sites, using atelopeptide type-I collagen (CL) as a carrier (BMP groups). CL implantation was used as a control. Forty Wistar rats were divided into intramuscular, intermuscular, subcutaneous and intrafatty site groups (IrM, IeM, SC and IF, respectively). Bone formation was evaluated radiographically, histologically and biochemically 21 days after implantation. In the BMP groups, the alkaline phosphatase activity and calcium content at all sites were higher than those in the control groups. Among the BMP groups, the new bone formation was highest in the IrM and lowest in the IF radiographically, histologically and biochemically. Five microg of rhBMP-2, a relatively low dose, induced adequate new bone formation in all sites. The variations of osteoinductive activity of rhBMP-2 in various sites may be due to differences in the blood supply.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Japan. okubo@kuhp.kyoto-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Okubo
authors.forename: K
authors.initials: K
authors.lastname: Bessho
authors.forename: K
authors.initials: K
authors.lastname: Fujimura
authors.forename: Y
authors.initials: Y
authors.lastname: Konishi
authors.forename: K
authors.initials: K
authors.lastname: Kusumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Iizuka
mesh_terms: D000273:Adipose Tissue / Q000737:chemistry / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D000469:Alkaline Phosphatase / Q000032:analysis; D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D002118:Calcium / Q000032:analysis; D003094:Collagen; D004337:Drug Carriers; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000737:chemistry / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D009999:Ossification, Heterotopic / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects*; D011859:Radiography; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D012867:Skin / Q000737:chemistry / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C059821:atelocollagen; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen; D000469:Alkaline Phosphatase; D002118:Calcium